Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki, 852-8588, Japan; Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki, 852-8588, Japan.
Drug Metab Pharmacokinet. 2022 Jun;44:100450. doi: 10.1016/j.dmpk.2022.100450. Epub 2022 Feb 5.
Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed.
脂质纳米颗粒 (LNPs) 作为一种传递治疗剂的手段越来越受欢迎,包括基于核酸和 mRNA 的治疗剂。基于 mRNA 的 2019 年冠状病毒病疫苗就是突出药物传递系统在增进人类健康方面所起作用的完美范例。LNPs 用于传递核酸和基于 mRNA 的治疗剂的基本原理已经确立。因此,未来对 LNPs 的研究将集中在以下几个方面:将药物传递的范围扩大到人体的不同组成部分,扩大可以靶向的疾病数量,并研究 LNPs 在生理和病理条件下药代动力学的变化。本文综述了旨在扩大 LNPs 应用的最新进展,重点介绍了 LNPs 的药代动力学和优势。此外,还讨论了分析技术、文库构建和筛选、合理设计、主动靶向和基因编辑治疗的适用性。